EPO: EPO orders stay of proceedings

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

EPO: EPO orders stay of proceedings

As we have previously reported, one of the EPO's chemical boards of appeal has referred the issue of entitlement to partial priority to the Enlarged Board of Appeal. The case is pending before the Enlarged Board under reference G 1/15.

As part of the G 1/15 referral, the Enlarged Board will have to consider under which circumstances, if any, a generic OR-claim is entitled to priority from an earlier application for some – but not all – of the subject matter covered by the claim.

By a notice given on October 2 2015, the president of the EPO has now decided that, in view of the potential impact of the G 1/15 referral, all examination and opposition proceedings in which the decision depends entirely on the outcome of G 1/15 will be stayed ex officio until the Enlarged Board issues its decision.

Cases are affected in which:

  • an invention to which a claim is directed is not novel and/or inventive in the light of the prior art if the claim is not entitled to partial priority (in the case of divisional applications, the prior art may in this case for example include the application's own parent or divisional);

  • the claim in question encompasses, without spelling them out, alternative embodiments having all the features of the claim (known as a generic OR-claim);

  • the priority document discloses only one or more embodiments covered by the claim in question, that is the claim being a generalisation of the disclosure of the priority document, but wherein the priority document does not disclose the subject matter of the entire claim itself; and

  • the outcome of the proceedings depends entirely on how the Enlarged Board decides in case G 1/15.

The President's decision has immediate effect.

Jakob Pade Frederiksen


Inspicos A/S

Kogle Allé 2

DK-2970 Hoersholm

Copenhagen, Denmark

Tel: +45 7070 2422

Fax: +45 7070 2423

info@inspicos.com

www.inspicos.com

more from across site and SHARED ros bottom lb

More from across our site

Sim & San secured the win for Dr. Reddy’s, which will allow the pharma company to manufacture and export semaglutide, the active ingredient in Ozempic
Lucas Amodio joins our ‘Five minutes with’ series to discuss artificial intelligence systems and patent law
The Americas research cycle has commenced, so don't miss the opportunity to submit your work
Practitioners have welcomed extended funding of the specialist police unit until 2029, while the UKIPO says it is exploring increased scale
Abion says integration with Baylos marks an important step in the company’s international expansion plans
Via Licensing Alliance continues its China push as another smartphone manufacturer joins patent pool as licensee
Law firm mergers have the potential to reshape IP teams, and partners who were at the coalface of previous tie-ups say early coordination and flexibility can make the difference
Women are entering the IP profession, but still too few are being trusted with the clients, cases, and credit that may open the path to leadership
In other news, Australia’s IP office has announced expanded search options, and an EPO report shed light on slow progress relating to women inventors in Europe
Managing IP speaks with up-and-coming women lawyers at five law firms about fighting imposter syndrome, maintaining work-life balance and why real representation matters
Gift this article